{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"13.8","value":"7.6"},{"groupId":"OG001","lowerLimit":"2.7","upperLimit":"9.0","value":"4.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"description":"Defined as the time from the date of randomization to the date of documented disease progression","dispersionType":"Inter-Quartile Range","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"},{"description":"Placebo in combination with capecitabine \\& trastuzumab","id":"OG001","title":"Pbo+Cap+Tra"}],"paramType":"MEDIAN","populationDescription":"ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.","reportingStatus":"POSTED","timeFrame":"Up to 58.0 months","title":"PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Final Analysis","type":"SECONDARY","unitOfMeasure":"months"}